Clinical Trials

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07120698 2026-01-05

CTONG 2508

115 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07061535 2025-07-11

STAR-SCLC

40 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

506 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04836728 2025-03-13

CCICC-002b

156 enrolled

Non-small Cell Lung Cancer Metastatic

NCT03812549 2025-03-04

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

160 enrolled

Locally Advanced Non-Small Cell Lung Cancer

NCT05549037 2025-02-19

PACIFIC15

Phase 3 Recruiting

210 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Phase 1 Recruiting

144 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06747169 2024-12-27

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

32 enrolled

Squamous Non-Small Cell Lung Cancer SqNSCLC

NCT03872661 2024-12-06

NIBCUN

36 enrolled

Lung Neoplasms

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05979818 2024-11-19

BRIO

Phase 1 Recruiting

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06688656 2024-11-14

Peri-E

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

45 enrolled

Lung Neoplasms

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

296 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04167657 2024-09-19

STAR

Phase 2 Completed

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

39 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05244213 2024-07-08

NEOTIDE

35 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

90 enrolled

Resectable Non-small Cell Lung Cancer

NCT06479759 2024-06-28

ACCLAIM

50 enrolled

NSCLC

NCT06421298 2024-05-20

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Neoplasms

NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

20 enrolled

Advanced Non Small Cell Lung Cancer

NCT06267144 2024-02-20

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04326153 2024-02-01

Neo-Pre-IC

IIIA Stage Non-small Cell Lung Cancer

NCT06221462 2024-01-25

PRIORITY

Carcinoma, Non-Small-Cell Lung

NCT05088967 2024-01-16

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Phase 1 Terminated

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03802240 2023-11-27

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

492 enrolled

Non-Squamous Non-Small Cell Lung Cancer

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

21 enrolled

Lung Neoplasms

NCT04728724 2023-09-13

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

105 enrolled

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

60 enrolled

SCLC

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

19 enrolled

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

42 enrolled

Advanced Lung Cancer

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

290 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

357 enrolled 14 charts

Squamous NSCLC

NCT03607539 2023-02-27

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

397 enrolled 15 charts

Lung Neoplasms

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT05429463 2022-12-14

neoSCORE Ⅱ

Phase 3 Recruiting

250 enrolled

Squamous Cell Non-small Cell Lung Cancer

NCT05648071 2022-12-13

SPBPDC

Phase 3 Unknown

60 enrolled

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

9 enrolled

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT05527821 2022-09-06

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

36 enrolled

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04459611 2022-07-12

neoSCORE

60 enrolled